Moomoo AIのまとめ
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce...Show More
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce operational expenditures, including labor expense reductions and facility consolidations, expected to commence in the second quarter of 2024. Additionally, Ginkgo acquired platform assets from AgBiome, Inc. on April 10, 2024, to enhance its Ag Biologicals Services. Looking forward, Ginkgo Bioworks aims to leverage its Foundry and Codebase assets to drive scale and learning efficiencies across diverse markets, with a focus on improving the probability of successful product development for its customers.
Ginkgo Bioworks Holdings, Inc.は、2024年3月31日に終了した第1四半期の総売上高が減少し、売上高が$8,070.2万から$3,794.4万に下落しました。同社の細胞工学部門の売上高は$3,409.6万から$2,788.9万に減少し、バイオセキュリティ部門の売上高は$4,660.6万から$1,005.5万に大幅に減少しました。セグメントの合計営業損失は前年比で$11,641万から$12,366.2万に拡大しました。希薄化後の1株当たりの純損失は$0.08で一定であり、前年度の1株当たりの純損失$0.11から改善しました。Ginkgo Bioworksはまた、20...すべて展開
Ginkgo Bioworks Holdings, Inc.は、2024年3月31日に終了した第1四半期の総売上高が減少し、売上高が$8,070.2万から$3,794.4万に下落しました。同社の細胞工学部門の売上高は$3,409.6万から$2,788.9万に減少し、バイオセキュリティ部門の売上高は$4,660.6万から$1,005.5万に大幅に減少しました。セグメントの合計営業損失は前年比で$11,641万から$12,366.2万に拡大しました。希薄化後の1株当たりの純損失は$0.08で一定であり、前年度の1株当たりの純損失$0.11から改善しました。Ginkgo Bioworksはまた、2024年4月10日にAgBiome, Inc.からプラットフォーム資産を取得し、Agバイオロジカルサービスを強化しました。今後、Ginkgo Bioworksはファンドリーとコードベースの資産を活用し、多様な市場にわたってスケールと学習効率を推進し、顧客の製品開発の成功確率を向上することを目指しています。同社は人件費削減や施設の統合などのオペレーショナル支出を削減する再構築措置を行い、2024年第2四半期に開始する予定です。
役に立った
役に立たない
